Zydus Claims Exclusivities After A Pair Of US Approvals
Gets Nod For First Generic Ibrutinib Capsules And Macitentan Tablets
Zydus Cadila has claimed eligibility for periods of 180-day exclusivity linked to two of its recent US generic approvals, for rivals to Imbruvica and Opsumit.
